Almorexant

Overview

Almorexant is a drug that was developed as a dual orexin receptor antagonist (DORA) for the treatment of insomnia. Orexins are neuropeptides that play a crucial role in regulating the sleep-wake cycle and arousal. By blocking the action of orexins, almorexant promotes sleep.

Mechanism of Action

Almorexant works by inhibiting the binding of orexins to their receptors, specifically orexin receptor 1 (OX1R) and orexin receptor 2 (OX2R). This inhibition reduces the wake-promoting effects of orexins, thereby facilitating the onset and maintenance of sleep.

Development and Clinical Trials

Almorexant was developed by Actelion Pharmaceuticals in collaboration with GlaxoSmithKline. It underwent several clinical trials to assess its efficacy and safety in treating insomnia. However, despite initial promising results, the development of almorexant was discontinued due to concerns about its safety profile, including potential liver toxicity.

Pharmacokinetics

The pharmacokinetic profile of almorexant includes its absorption, distribution, metabolism, and excretion. Almorexant is administered orally and is metabolized primarily in the liver. The drug's half-life and bioavailability were key considerations during its development.

Side Effects

Common side effects observed in clinical trials of almorexant included drowsiness, headache, and dizziness. More serious adverse effects, such as liver enzyme elevation, led to the discontinuation of its development.

Potential Applications

While almorexant itself is no longer being developed, the concept of orexin receptor antagonism remains a promising avenue for the treatment of insomnia and other sleep disorders. Other DORAs are currently being investigated for their therapeutic potential.

Related Pages

• Orexin receptor antagonist
• Insomnia
• Sleep disorder
• Actelion Pharmaceuticals
• GlaxoSmithKline

Chemical structure of almorexant